Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


75P - Karyopherin Alpha 2 Role in Determining Outcome for Patients with Bladder Cancer: A Systematic Review and Meta-Analysis


06 Oct 2021




Alexa Tan


Annals of Oncology (2021) 32 (suppl_6): S1345-S1371. 10.1016/annonc/annonc740


A.O. Tan1, J.H. Wijaya2

Author affiliations

  • 1 UPH - Pelita Harapan University, Tangerang/ID
  • 2 UPH - Pelita Harapan University, 15811 - Tangerang/ID

Abstract 75P


The prognostic variables for bladder cancer recurrence and survival are few and contradictory at this time. KPNA2 is a member of the karyopherin (importin) family. However, there is presently no relevant study on KPNA2 expression in bladder cancer. The objective of this systematic review and meta-analysis was to investigate the predictive value of KPNA2 in bladder tumor patients.


According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline, we ran a comprehensive scientific writing search on the topic of KPNA2 and bladder cancer. From EuroPMC, ScienceDirect, and PubMed, 60,5668 were retrieved by the authors using the search terms of KPNA2, karyopherin alpha 2, prognosis, outcome, bladder, urothelial, “transitional cell”, cancer, carcinoma, neoplas*, and tumor. The inclusion criteria are individuals who have bladder cancer with proof of tissue biopsy, reported the status of KPNA2, reported the key exposure, published in full text on the English language, and adult population. We excluded preprints, abstract-only, and any paper considered as grey or white literature. Strong nuclear staining in at least 10% of the carcinoma cells was classified as high KPNA2 expression. The key exposure of this study is disease-free survival (DFS), overall survival (OS), and tumor recurrence. We analyzed the hazard ratio (HR) data and reported it as HR along with a 95% confidence interval (CI). The data were analyzed using the random-effects model. In all of the papers reviewed, the Newcastle Ottawa Scale (NOS) was used to assess the overall quality of evidence.


Current study compromises 1009 samples, with 549 of them considered low expression of KPNA2. 656 were female and 372 were T1. From meta-analysis, we found that KPNA2 was associated with DFS (HR 2.16 [0.93, 5.04]; p=0.010); I2 = 85%) and tumor recurrence (HR 1.99 [0.96, 4.13]; p=0.04); I2 = 75%), but not with OS (HR 1.65 [1.21, 2.24]; p=0.18); I2 = 42%).


This study demonstrated that KPNA2 was associated with disease-free survival and tumor recurrence, but not overall survival rate. However, the authors admit the small cohort available; henceforth, more studies with larger sample size and prospective design are suggested.

Legal entity responsible for the study

A.O. Tan.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.